The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Allogeneic T Cell Therapies Market By 2030 Starting From Its 2026 Size?
The allogeneic t cell therapies market has shown robust growth over recent years. It is anticipated to expand from $1.26 billion in 2025 to $1.38 billion in 2026, at a compound annual growth rate (CAGR) of 9.4%. This historical growth can be attributed to various factors, including the limitations of autologous therapies, the initial success of CAR-T treatments, an increase in cancer prevalence, progress in immunotherapy research, and the widening reach of hospital-based oncology.
The allogeneic t cell therapies market is anticipated to experience robust expansion over the coming years, reaching a valuation of $1.98 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.4%. This projected increase is primarily driven by factors such as the rising demand for cost-effective cell therapies, the expanding array of oncology pipelines, advancements in donor matching techniques, ongoing regulatory encouragement for cell therapies, and the proliferation of specialty cancer centers. Key developments expected during this timeframe encompass a notable shift towards off-the-shelf cell therapy solutions, an increase in oncology-related clinical trials, a heightened emphasis on scalable cell manufacturing processes, greater investment in cell engineering innovations, and the further establishment of specialized treatment facilities.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18952&type=smp
What Drivers Are Shaping The Future Growth Of The Allogeneic T Cell Therapies Market?
The future expansion of the allogeneic T cell therapies market is anticipated to be driven by the rising incidence of cancer. Cancer is defined as a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells throughout the body. The uptick in cancer diagnoses can be attributed to several factors including extended lifespans, evolving lifestyles, exposure to environmental agents, various infections, inherited genetic predispositions, and shifts in reproductive behaviors, all of which together lead to a greater occurrence and identification of the condition. In cancer treatment, allogeneic T cell therapies are employed to pinpoint and eliminate malignant cells through the introduction of genetically modified donor T cells, which are designed to identify particular tumor antigens. As an example, the National Cancer Institute, a US-based government agency, reported approximately 18.1 million cancer survivors in the United States in May 2024. This count is predicted to climb to 22.5 million by 2032. Furthermore, by 2040, annual new cancer diagnoses are projected to hit 29.9 million, alongside an estimated increase in cancer-related fatalities to 15.3 million. Consequently, the expanding prevalence of cancer acts as a primary catalyst for the allogeneic T cell therapies market.
Which Segment Categories Define The Allogeneic T Cell Therapies Market?
The allogeneic t cell therapies market covered in this report is segmented –
1) By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies, T Cell Receptor (TCR) Therapies
2) By Antigen Type: CD 19, CD 20, Egfrvlll, GD2, CD22, CD30, CD33, Meso, HER1, Other Antigen Types
3) By Therapeutics Indications: Cancer, Autoimmune Diseases, Infectious Diseases, Other Therapeutics Indications
4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Chimeric Antigen Receptor (CAR) T Cell Therapies: CD19-targeted CAR T Therapies, BCMA-targeted CAR T Therapies, CD22-targeted CAR T Therapies
2) By T Cell Receptor (TCR) Therapies: Neoantigen-targeted TCR Therapies, Viral Antigen-targeted TCR Therapies
What Major Market Trends Are Driving Changes In The Allogeneic T Cell Therapies Market?
Leading companies operating in the allogeneic T cell therapies market are prioritizing the development of advanced products, such as gene-edited donor-derived CAR-T and TCR T cell therapies, aiming to gain a competitive edge. These gene-edited donor-derived T cell therapies involve immune-effector T cells sourced from healthy donors that are genetically manipulated (e.g., by knocking out T cell receptor (TCR) and HLA genes, inserting CAR/TCR constructs, and integrating safety switches) to create universal off-the-shelf products. These products can be manufactured in bulk, cryopreserved, and administered rapidly without requiring patient-specific manufacture. For instance, in January 2024, Allogene Therapeutics, a US-based cell therapy company, announced its 2024 platform vision centered on ALPHA3, which is the industry’s first pivotal trial for an allogeneic CAR-T program that utilizes gene-editing technologies to eliminate graft-versus-host disease (GvHD) risk and enable rapid donor-based delivery. The product’s features include donor-derived T cells edited to remove endogenous TCR and HLA molecules, thereby reducing host immune rejection and GvHD. It also incorporates a chimeric antigen receptor targeting a tumor antigen to allow prompt anti-cancer activity, and it is provided in a cryopreserved ready-to-infuse format to shorten the time to treatment when compared to autologous therapies.
Who Are The Top Companies Competing In The Allogeneic T Cell Therapies Market?
Major companies operating in the allogeneic t cell therapies market are Allogene Therapeutics Inc., Cellectis SA, Fate Therapeutics Inc., Poseida Therapeutics Inc., Atara Biotherapeutics Inc., Autolus Therapeutics Plc, Adaptimmune Therapeutics Plc, Immatics NV, Medigene AG, Celyad Oncology SA, Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Sangamo Therapeutics Inc., MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Bellicum Pharmaceuticals Inc., Enlivex Therapeutics Ltd., Sorrento Therapeutics Inc.
Read the full allogeneic t cell therapies market report here:
https://www.thebusinessresearchcompany.com/report/allogeneic-t-cell-therapies-global-market-report
Which Geographic Regions Are Influencing Demand In The Allogeneic T Cell Therapies Market?
North America was the largest region in the allogeneic T cell therapies market in 2025. The regions covered in the allogeneic t cell therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Allogeneic T Cell Therapies Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=18952&type=smp
Browse Through More Reports Similar to the Global Allogeneic T Cell Therapies Market 2026, By The Business Research Company
Allogeneic Cell Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report
Cells Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report
Cell Therapy Technologies Market Report 2026
https://www.thebusinessresearchcompany.com/report/cell-therapy-technologies-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model